Plain language summary of the himalaya study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

dc.contributor.author	Abou-Alfa, Ghassan K.
dc.contributor.author	Lau, George
dc.contributor.author	Kudo, Masatoshi
dc.contributor.author	Varela Calvo, María
dc.date.accessioned	2024-04-18T07:21:13Z
dc.date.available	2024-04-18T07:21:13Z
dc.date.issued	2023
dc.identifier.citation	Future Oncology, 19(38) (2023); doi:10.2217/fon-2023-0486
dc.identifier.issn	1479-6694
dc.identifier.issn	1744-8301
dc.identifier.uri	https://hdl.handle.net/10651/72239
dc.description.statementofresponsibility	Abou-Alfa G.K., Lau G., Kudo M., Chan S.L., Kelley R.K., Furuse J., Sukeepaisarnjaroen W., Kang Y.K., Van Dao T., De Toni E.N., Rimassa L., Breder V., Vasilyev A., Heurgué A., Tam V.C., Mody K., Thungappa S.C., Ostapenko Y., Yau T., Azevedo S., Varela M., Cheng A.-L., Qin S., Galle P.R., Ali S., Gupta C., Makowsky M., Kurland J.F., Negro A., Sangro B.
dc.language.iso	eng
dc.relation.ispartof	Future Oncology
dc.rights	© 2023 AstraZeneca and co-authors
dc.rights	CC Reconocimiento – No Comercial – Sin Obra Derivada 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	WOS:001062933700001
dc.title	Plain language summary of the himalaya study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
dc.type	journal article
dc.identifier.doi	10.2217/fon-2023-0486
dc.relation.publisherversion	http://dx.doi.org/10.2217/fon-2023-0486
dc.rights.accessRights	open access
dc.type.hasVersion	VoR

Este ítem está sujeto a una licencia Creative Commons